{'fraction_non_alphanumeric': 0.023383768913342505, 'fraction_numerical': 0.015130674002751032, 'mean_word_length': 5.222222222222222, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Articles of Significant Interest Selected from This Issue by the Editors

The Ebola virus surface glycoprotein GP contains a large, heavily glycosylated mucin-like domain that is immunodominant in vaccination studies. Antibodies that recognize this domain generally do not neutralize but, curiously, can be protective in animal models. Olal et al. (p. 2809 –2816) determined the crystal structure of one such antibody, MAb 14G7, in complex with its linear GP epitope. The mucin domain peptide binds deeply into a cleft in the antibody combining site, maximizing surface contact for a minimal number of residues. This work provides a structural framework for analysis and improvement of candidate Ebola virus immunotherapeutics.